Matthew Kang, MD, FRCPC - Putting the Individual in ITP: Enhancing Patients Outcomes With TPO-RAs
11m
·
PeerVoice Oncology & Haematology Video
·
Matthew Kang, MD, FRCPC - Putting the Individual in ITP: Enhancing Patients Outcomes With TPO-RAs
The episode Matthew Kang, MD, FRCPC - Putting the Individual in ITP: Enhancing Patients Outcomes With TPO-RAs from the podcast PeerVoice Oncology & Haematology Video has a duration of
11:14. It was first published
More episodes from PeerVoice Oncology & Haematology Video
Mohamed El-Hussein, RN, PhD, NP / Caitlin Carreau, MN, RN(EC) - At the Forefront of Cancer Prevention: Nursing Strategies to Optimize HPV Immunization
Mohamed El-Hussein, RN, PhD, NP / Caitlin Carreau, MN, RN(EC) - At the Forefront of Cancer Prevention: Nursing Strategies to Optimize HPV Immunization
Jeffrey Habert, MD, CCFP, FCFP - Steps Towards Earlier Detection of Lung Cancer: Harnessing the Power of Primary Care
Jeffrey Habert, MD, CCFP, FCFP - Steps Towards Earlier Detection of Lung Cancer: Harnessing the Power of Primary Care
Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents
Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents
Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy
Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy
Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics
Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics